Atrium Therapeutics, Inc.
RNA
$10.51
-$0.84-7.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -21.91% | 1,148.25% | -71.11% | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -21.91% | 1,148.25% | -71.11% | ||
| Cost of Revenue | 15.42% | 140.12% | 90.03% | ||
| Gross Profit | -30.63% | 155.52% | -195.40% | ||
| SG&A Expenses | 200.73% | 870.21% | 819.24% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 53.32% | 309.03% | 224.82% | ||
| Operating Income | -75.82% | -131.88% | -365.56% | ||
| Income Before Tax | -56.74% | -123.29% | -365.86% | ||
| Income Tax Expenses | -- | -- | -99.35% | ||
| Earnings from Continuing Operations | -56.74% | -123.29% | -153.09% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -56.74% | -123.29% | -153.09% | ||
| EBIT | -75.82% | -131.88% | -365.56% | ||
| EBITDA | -74.23% | -131.50% | -367.95% | ||
| EPS Basic | -56.74% | -123.28% | -- | ||
| Normalized Basic EPS | -56.71% | -123.25% | -- | ||
| EPS Diluted | -56.74% | -123.28% | -- | ||
| Normalized Diluted EPS | -56.71% | -123.25% | -- | ||
| Average Basic Shares Outstanding | 0.00% | 0.00% | -- | ||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||